Taysha Gene Therapies, Inc.
TSHA • NASDAQ
Taysha Gene Therapies, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Sean Nolan, with a market cap of $1.2B.
CEOSean Nolan
Next Earnings
Upcoming earnings announcement for Taysha Gene Therapies, Inc.
Date
Thursday, May 14, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.10
Revenue Estimate
$827.3K
Earnings History
Past 12 earnings reports for Taysha Gene Therapies, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$0.12Est: -$0.10 | -20.0% | $5.5MEst: $1.9M | +190.4% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.09Est: -$0.09 | 0.0% | -Est: $1.4M | -100.0% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.09Est: -$0.07 | -28.6% | $2.0MEst: $1.7M | +20.3% | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.08Est: -$0.09 | +11.1% | $2.3MEst: $1.4M | +70.4% | 10-Q |
| Feb 26, 2025 | Q4 2024 | -$0.07Est: -$0.08 | +12.5% | $2.0MEst: $1.9M | +6.4% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.10Est: -$0.09 | -11.1% | $1.8MEst: $1.7M | +8.4% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.09Est: -$0.17 | +47.1% | $1.1MEst: $2.7M | -58.2% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.10Est: -$0.11 | +9.1% | $3.4MEst: $2.6M | +33.2% | 10-Q |
| Mar 19, 2024 | Q4 2023 | $0.92Est: -$0.11 | +936.4% | $3.6MEst: $2.7M | +36.0% | 10-K |
| Nov 14, 2023 | Q3 2023 | -$0.93Est: -$0.17 | -447.1% | $4.7MEst: $1.4M | +239.0% | — |
| Aug 14, 2023 | Q2 2023 | -$0.38Est: -$0.31 | -22.6% | $2.4MEst: $2.0M | +19.8% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.28Est: -$0.35 | +20.0% | $4.7MEst: $70.0K | +6622.9% | — |